Human Gene Set: VAN_DEN_BIGGELAAR_PBMC_PREVNAR_9MO_INFANT_STIMULATED_VS_UNSTIMULATED_9MO_DN


Standard name VAN_DEN_BIGGELAAR_PBMC_PREVNAR_9MO_INFANT_STIMULATED_VS_UNSTIMULATED_9MO_DN
Systematic name M40949
Brief description Genes down-regulated in peripheral blood mononuclear cell stimulated vs unstimulated in infants (9m) after exposure to Prevnar (USA) , time point 9M and 8M (identical response signature)
Full description or abstract Concerns about the risk of inducing immune deviation-associated neonatal tolerance as described in mice have restricted the widespread adoption of neonatal vaccination. The aim of this study was to demonstrate the immunological feasibility of neonatal pneumococcal conjugate vaccination (PCV) which could potentially protect high-risk infants in resource poor countries against severe pneumococcal disease and mortality in the early critical period of life. Papua New Guinean infants were randomized to be vaccinated with the 7-valent PCV (7vPCV) at birth, 1 and 2 months (neonatal group, n=104) or at 1, 2 and 3 months of age (infant group, n=105), or to not receive 7vPCV at all (control group, n=109). Analysis of vaccine responses at 3 and 9 months of age demonstrated persistently higher type-1 (IFN-gamma) and type-2 (IL-5 and IL-13) T-cell responses to the protein carrier CRM(197) and IgG antibody titres to 7vPCV serotypes in children vaccinated with 7vPCV according to either schedule as compared to unvaccinated children. In a comprehensive immuno-phenotypic analysis at 9 months of age, no differences in the quantity or quality of vaccine-specific T cell memory responses were found between neonatal vaccinations versus children given their first PCV dose at one month. Hospitalization rates in the first month of life did not differ between children vaccinated with PCV at birth or not. These findings demonstrate that neonatal 7vPCV vaccination is safe and not associated with immunological tolerance. Neonatal immunisation schedules should therefore be considered in high-risk areas where this may result in improved vaccine coverage and the earliest possible protection against pneumococcal disease and death.
Collection C7: Immunologic Signature
      VAX: HIPC Vaccine Response
Source publication Pubmed 21645573   Authors: van den Biggelaar AH,Pomat W,Bosco A,Phuanukoonnon S,Devitt CJ,Nadal-Sims MA,Siba PM,Richmond PC,Lehmann D,Holt PG
Exact source  
Related gene sets (show 2 additional gene sets from the source publication)

(show 12 gene sets from the same authors)
External links
Filtered by similarity ?
Source species Homo sapiens
Contributed by HIPC SIGNATURES (NIAID/HIPC SIGNATURES)
Source platform or
identifier namespace
HUMAN_GENE_SYMBOL
Dataset references  
Download gene set format: grp | gmt | xml | json | TSV metadata
Compute overlaps ? (show collections to investigate for overlap with this gene set)
Compendia expression profiles ? NG-CHM interactive heatmaps
(Please note that clustering takes a few seconds)
GTEx compendium
Human tissue compendium (Novartis)
Global Cancer Map (Broad Institute)
NCI-60 cell lines (National Cancer Institute)

Legacy heatmaps (PNG)
GTEx compendium
Human tissue compendium (Novartis)
Global Cancer Map (Broad Institute)
NCI-60 cell lines (National Cancer Institute)
Advanced query Further investigate these 5 genes
Gene families ? Categorize these 5 genes by gene family
Show members (show 5 source identifiers mapped to 5 genes)
Version history 7.3: First Introduced.

See MSigDB license terms here. Please note that certain gene sets have special access terms.